In the management of lung cancer, particularly, two advanced technologies, Flaura osimertinib and Guardant, have revolutionized the field of cancerology.For EGFR-mutated lung cancer (non-small cell lung cancer), osimertinib is a specific therapy.Guardant, as a next-gen sequencing (NGS) test, helps in diagnosing and monitoring cancer mutations.The basics of Flaura osimertinib (also known as Tagrisso) are to be understood.For the treatment of late-stage non-small cell lung cancer (non-small cell lung cancer), Flaura osimertinib, known as Tagrisso, is a third generation EGFR kinase inhibitor (TKI).It is designed to target specific mutations in the…
